NCT07365501Enrolling by invitation
Acute Effect of Nurse-assessed Remote Ischemic Preconditioning on Improving Vascular Parameters in Patients With Suspected Heart Failure With Preserved Ejection Fraction
Source: ClinicalTrials.gov · Last updated 6 Mar 2026
Brief summary (registry, in English)
The PIRIC-FEp study will be a randomized clinical trial in sedentary patients with suspected heart failure with preserved ejection fraction. Objectives: 1) To evaluate the acute efficacy of remote ischemic preconditioning performed by nurses, a noninvasive cardioprotective intervention that uses cycles of ischemia and reperfusion in the extremities, in improving vascular parameters. Methodology: Patients will be recruited in Health Centers in the city. Those assigned to the intervention group will wear a self-administered blood pressure cuff, inflated to 220 mmHg for 5 minutes, followed by 5 minutes of deflation, in repeated cycles four times. The control group will receive no intervention. All participants will be examined, at baseline, 0 minutes post intervention, 30 minutes post intervention, 60 minutes post intervention and 24 hours post intervention. Different vascular parameters will be evaluated, including peripheral and central Systolic and Blood Pressure, peripheral and central Mean Arterial Pressure, peripheral and central Pulse Pressure, Heart Rate, Cardiac Output, Stroke Volume, Peripheral Vascular Resistance, aortic Pulse Wave Velocity and Augmentation Index normalized to a heart rate of 75 beats per minute. The study will be approved by an Ethics Committee, participants will be informed and will have to sign a written consent. The statistical analysis will include three phases: verification of randomization, use of covariance models for dependent variables, and sensitivity analysis with propensity score matching. All analyses will be performed on an intention-to-treat basis.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- First submitted
- 16 Jan 2026
- Start date
- 1 Oct 2025
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- University of Castilla-La Mancha
- Diseases
- Heart failure
- NCT number
- NCT07365501
What you commit to
- Study type: Interventional
- Planned participants: 48
- From 1 Oct 2025 to the primary completion date, 28 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Non-cardiac causes of Heart Failure symptoms:
- Significant valvular or coronary artery disease
- Uncontrolled hypertension or arrhythmias
- Primary cardiomyopathies
- Significant pulmonary disease (FEV1\<50% predicted, GOLD III-IV)
- Inability to exercise or conditions that may interfere with exercise intervention.
- Myocardial infarction within the last 3 months.
- Patients with diabetes and/or peripheral vascular disease.
Other
- Comorbidity that may influence prognosis at one year.
- Participation in another clinical trial
Who the study is looking for
- Signs and symptoms of Heart Failure (Clinical suspicion of Heart Failure)
- Sedentary men and women (structured exercise \<2 x 30 min/week).
- Age ≥40 years
- Written informed consent
- Clinically stable for 6 weeks
- Optimal medical treatment for ≥6 weeks.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Iván Coordinator of this site? Confirm its status | Cuenca | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.